Q-omics provides the consensus-scored WNT11 profile across patient tissues and cancer cell-line models. WNT11 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, WNT11 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, WNT11 protein abundance shows 21,789 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight BLCA, KIRC, and LUAD as cancer lineages where WNT11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WNT11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WNT11 survival associations across molecular data types. WNT11 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WNT11 RNA expression–survival associations across cancer types. High WNT11 expression shows unfavorable associations in BLCA, OV, SKCM, READ and THCA, but favorable associations in HNSC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for WNT11 RNA expression.
This table summarizes WNT11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 10. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for WNT11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WNT11 shows lower tumor expression in KIRC, THCA, BRCA, LUAD and LIHC and higher tumor expression in COAD. The KIRC box plot shows higher WNT11 RNA expression in normal versus tumor tissue (log2 FC = −1.414, t-test p < 0.001).
This table shows molecular features associated with WNT11 in patient tissues and cancer cell lines. In patient samples, WNT11 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, WNT11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
